Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin's Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
01 Mar 2023
Historique:
received: 06 02 2023
revised: 25 02 2023
accepted: 27 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

Non-Hodgkin's lymphomas are a diverse collection of lymphoproliferative cancers that are much less predictable than Hodgkin's lymphomas with a far greater tendency to metastasize to extranodal sites. A quarter of non-Hodgkin's lymphoma cases develop at extranodal sites and the majority of them involve nodal and extranodal sites. The most common subtypes include follicular lymphoma, chronic/small lymphocytic leukaemia, mantel cell lymphoma, and marginal zone lymphoma. Umbralisib is one of the latest PI3Kδ inhibitors in clinical trials for several hematologic cancer indications. In this study, new umbralisib analogues were designed and docked to the active site of PI3Kδ, the main target of the phosphoinositol-3-kinase/Akt/mammalian target of the rapamycin pathway (PI3K/AKT/mTOR). This study resulted in eleven candidates, with strong binding to PI3Kδ with a docking score between -7.66 and -8.42 Kcal/mol. The docking analysis of ligand-receptor interactions between umbralisib analogues bound to PI3K showed that their interactions were mainly controlled by hydrophobic interactions and, to a lesser extent, by hydrogen bonding. In addition, the MM-GBSA binding free energy was calculated. Analogue 306 showed the highest free energy of binding with -52.22 Kcal/mol. To identify the structural changes and the complexes' stability of proposed ligands, molecular dynamic simulation was used. Based on this research finding, the best-designed analogue, analogue 306, formed a stable ligand-protein complex. In addition, pharmacokinetics and toxicity analysis using the QikProp tool demonstrated that analogue 306 had good absorption, distribution, metabolism, and excretion properties. Additionally, it has a promising predicted profile in immune toxicity, carcinogenicity, and cytotoxicity. In addition, analogue 306 had stable interactions with gold nanoparticles that have been studied using density functional theory calculations. The best interaction with gold was observed at the oxygen atom number 5 with -29.42 Kcal/mol. Further in vitro and in vivo investigations are recommended to be carried out to verify the anticancer activity of this analogue.

Identifiants

pubmed: 36903539
pii: molecules28052289
doi: 10.3390/molecules28052289
pmc: PMC10005307
pii:
doi:

Substances chimiques

Phosphoinositide-3 Kinase Inhibitors 0
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Gold 7440-57-5
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Ligands 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : This study is supported via funding from Prince Sattam bin Abdulaziz University. Project number (PSAU/2023/R/1444).
ID : PSAU/2023/R/1444

Références

Ann Hematol. 2019 Jan;98(1):175-183
pubmed: 30315345
ACS Omega. 2021 Jan 04;6(2):1235-1245
pubmed: 33490782
Chem Sci. 2020 May 19;11(23):5855-5865
pubmed: 32953006
Pharmacol Res. 2021 Nov;173:105900
pubmed: 34547385
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300
pubmed: 34096718
J Biol Chem. 2015 Mar 27;290(13):8439-46
pubmed: 25631052
Drugs. 2021 May;81(7):857-866
pubmed: 33797740
Front Nutr. 2022 Apr 22;9:889276
pubmed: 35529456
Cancer Manag Res. 2018 Mar 27;10:615-624
pubmed: 29628774
J Med Chem. 2019 May 23;62(10):4783-4814
pubmed: 30582813
Mayo Clin Proc. 2015 Aug;90(8):1152-63
pubmed: 26250731
J Chem Inf Model. 2019 Sep 23;59(9):3782-3793
pubmed: 31404495
Expert Opin Ther Pat. 2021 Oct;31(10):877-892
pubmed: 33970742
Inform Med Unlocked. 2021;26:100725
pubmed: 34514079
Expert Opin Pharmacother. 2022 Apr;23(5):535-541
pubmed: 35209784
Nucleic Acids Res. 2018 Jul 2;46(W1):W257-W263
pubmed: 29718510
Heliyon. 2020 Oct 01;6(9):e04978
pubmed: 33033767
J Family Med Prim Care. 2020 Apr 30;9(4):1834-1840
pubmed: 32670927
Front Oncol. 2019 Jun 04;9:443
pubmed: 31214498
Eur J Med Chem. 2020 Dec 15;208:112865
pubmed: 32987316
Mol Pharm. 2019 Jan 7;16(1):1-23
pubmed: 30452861
Drug Des Devel Ther. 2018 Aug 21;12:2577-2590
pubmed: 30174412
J Med Chem. 2006 Oct 19;49(21):6177-96
pubmed: 17034125
Blood. 2017 Jan 5;129(1):88-99
pubmed: 27784673
Drug Des Devel Ther. 2017 Aug 31;11:2551-2564
pubmed: 28919707
Curr Neuropharmacol. 2018;16(6):740-748
pubmed: 29046156
Biomolecules. 2019 Feb 26;9(3):
pubmed: 30813656
Cancers (Basel). 2022 Jun 13;14(12):
pubmed: 35740580
Lancet Oncol. 2018 Apr;19(4):486-496
pubmed: 29475723
Curr Pharm Biotechnol. 2021;22(8):1030-1045
pubmed: 32900347
Beilstein J Org Chem. 2016 Dec 12;12:2694-2718
pubmed: 28144341
Comput Biol Chem. 2019 Feb;78:190-204
pubmed: 30557817
Med Chem. 2019;15(6):588-601
pubmed: 30799792
Biochem Biophys Rep. 2022 Mar;29:101225
pubmed: 35128086
Molecules. 2018 Apr 28;23(5):
pubmed: 29710787
J Mol Model. 2019 Jul 23;25(8):242
pubmed: 31338599
Int J Nanomedicine. 2021 Sep 08;16:6205-6216
pubmed: 34526768
Acta Pharmacol Sin. 2022 Jan;43(1):209-219
pubmed: 33782541
Comput Struct Biotechnol J. 2020 Dec 25;19:568-576
pubmed: 33510862
Inform Med Unlocked. 2022;29:100870
pubmed: 35128036

Auteurs

Abdalrahim M Ali (AM)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.

Alaa A Makki (AA)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.

Walaa Ibraheem (W)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.

Mohammed Abdelrahman (M)

Department of Pharmaceutics, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.

Wadah Osman (W)

Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, University of Khartoum, Al-Qasr Ave, Khartoum 11111, Sudan.

Asmaa E Sherif (AE)

Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.

Ahmed Ashour (A)

Department of Pharmacognosy, Faculty of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.

Sabrin R M Ibrahim (SRM)

Preparatory Year Program, Department of Chemistry, Batterjee Medical College, Jeddah 21442, Saudi Arabia.
Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.

Kholoud F Ghazawi (KF)

Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah 24382, Saudi Arabia.

Waad A Samman (WA)

Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30078, Saudi Arabia.

Abdulrahim A Alzain (AA)

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Gezira, Gezira 12217, Sudan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH